Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Axelar AB Appoints Carl Harald Janson as CEO

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
Johan Harmenberg will continue as Axelar’s Chief Medical Officer.

Axelar AB has announced the appointment of Carl Harald Janson as new CEO.

“We are very pleased to have appointed Carl Harald Janson as our new CEO in Axelar AB”, says Göran Pettersson, Chairman of Axelar.

Pettersson continued, “Carl Harald has previously been a Member of the Board of Axelar. His broad experience in pharmaceutical development will be of great benefit to the company. Johan Harmenberg, CEO of Axelar since 2007, will continue as Chief Medical Officer.”

“I am excited to lead the experienced team of Axelar and to continue the development of AXL1717. I look forward to take this potential novel cancer treatment to proof-of-concept”, says Carl Harald Janson.

Janson continued, “I am also very pleased that Johan Harmenberg will continue as Chief Medical Officer.”

Carl Harald Janson also serves as CEO of Karolinska Developments fully owned oncology group KDev Oncology AB which includes Akinion Pharmaceuticals AB and GliGene AB.

He previously worked as Vice President Portfolio Management at Karolinska Development from 2008 to 2011. He holds an MD and PhD from Karolinska Institutet and is a Certified European Financial Analyst (CEFA) from Stockholm School of Economics.

Carl Harald has over 25 years of experience in medicine, pharmaceutical development and asset management at Astra Arcus, Danske Securities and Carnegie Investment Bank.

He currently serves as Board Director of Clanotech AB and Akinion Pharmaceuticals AB.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Axelar Announces Final Data from Phase II Study with AXL1717 in Lung Cancer
Company is planning to present more data from AXL-003 at scientific meetings during 2014.
Friday, December 27, 2013
Investigator Sponsored Phase I/II study of AXL1717 in Patients with Brain Tumors
Phase I/II study with AXL1717 started in the United States.
Thursday, April 25, 2013
Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!